Medpace Holdings, Inc. (MEDP) Stock
MEDP Key Statistics
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
CEO: August James Troendle. Company website
MEDP — Frequently Asked Questions
What is the MEDP stock price today?
Medpace Holdings, Inc. (MEDP) trades at $664.77, up 0.03% on the day, as of Nov 12, 2026 09:20 UTC.
What is Medpace Holdings, Inc.'s market cap?
Medpace Holdings, Inc. has a market capitalisation of $18.59B, calculated from the live MEDP share price and shares outstanding.
What is the P/E ratio of MEDP?
MEDP trades at a trailing P/E of 36.85, from earnings per share of $18.04 over the last twelve months.
How much revenue does Medpace Holdings, Inc. make?
Medpace Holdings, Inc. generated revenue of $2.84B over the trailing twelve months, which puts the stock at 6.55 times sales.
What is the 52-week range for MEDP?
MEDP has traded between $373.00 and $693.97 over the past 52 weeks, and the last price is 4.2% below that high.
Is Medpace Holdings, Inc. profitable?
Yes. Medpace Holdings, Inc. keeps 18.24% of revenue as net income over the trailing twelve months.
What is the analyst price target for MEDP?
Wall Street analysts rate MEDP Hold, with an average price target of $646.90, 2.7% below the current price.
What sector is Medpace Holdings, Inc. in?
Medpace Holdings, Inc. is classified under the Healthcare sector and the Medical - Diagnostics & Research industry, and is domiciled in US.
Who is the CEO of Medpace Holdings, Inc.?
August James Troendle is the chief executive of Medpace Holdings, Inc., which employs 6,600 people.
Where can I track MEDP in real time?
QFI Terminal shows MEDP with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See MEDP live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open MEDP in Terminal See plans